Infinimmune develops drugs from complete human antibodies. The therapeutic pipeline is built on antibodies produced by human immune systems, displaying a distinct approach compared to model organisms.

Infinimmune

Infinimmune | 1,178 followers on LinkedIn. Treating human disease with truly human therapeutics. | Treating human disease with truly human therapeutics.

Neela Patel

Chief Business Officer at Infinimmune

Tim Sullivan

Co-Founder, Infinimmune

Lance Hepler

Computational biology and assay development at Infinimmune

Andrew Hill

Our CEO & Co-Founder Wyatt McDonnell was on a panel at the LSX World Congress in Boston this week discussing the topic of Fast-Tracking Biotech Growth. Thanks to Jenny Holt at Ray Therapeutics, Inc. for doing a great job moderating and keeping the audience engaged! See you all at the next event! 🧬🧬 Thanks #LSXCongress for inviting us!

Our CEO Wyatt McDonnell will be speaking today at 11 am ET at LSX USA Congress , on the panel “What’s required to scale? Fast tracking biotech growth.” Looking forward to seeing everyone there!

Our Chief Business Officer Tim Sullivan was on an oncology partnering panel yesterday at LSX USA Congress in Boston. Don’t miss our CEO Wyatt McDonnell ’s panel today on “What is Required to Scale? Fast-Tracking Biotech Growth” at 11 am ET. View the Day 2 agenda here: https://lnkd.in/eu7VgYU7

We’re excited to welcome Tim Sullivan , Ph.D., as Chief Business Officer. Tim brings decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning. “We’re thrilled to have Tim lead Infinimmune’s business development efforts, driving strategic growth initiatives and fostering key partnerships to advance our mission of developing fully human antibody therapies,” said Wyatt McDonnell , CEO & Co-Founder, Infinimmune. “His deep industry knowledge and proven track record in business development and strategy will be invaluable as we continue to expand our capabilities and deliver innovative antibody therapies to patients.” “I am excited to join Infinimmune at such a dynamic time. The company’s commitment to pioneering advances in antibody development is truly inspiring, and I look forward to contributing to its continued success by leading our business development initiatives,” said Sullivan. Read the release: 👇👇 https://lnkd.in/eTqudaQT

Finding “Impossible” Antibodies in the Human Body In the June issue of GEN we highlighted Infinimmune a company that uses immuno-sequencing technology to sift through the human antibody repertoire and identify promising therapeutic candidates. The compnay was founded by scientists who saw opportunities to apply advanced technology directly to antibody drug discovery.

Genetic Engineering & Biotechnology News

Top founders create a sounding board for themselves and their team, who are experienced and thoughtful. Wyatt McDonnell and his co-founders of Infinimmune recently welcomed Neela Patel to the board. Her experience and openness to support the team is welcomed by Playground as we partner in supporting Infinimmune from series A to IPO and beyond. https://lnkd.in/eWcAxajx

Playground Global

Great conversation at #BIO2024 about AIs impact on the future of oncology drug development. Deep thanks to Wyatt McDonnell , Kamni Vijay, PhD , Daniel-Adriano S. , Andrei Georgescu, Ph.D. for an engaging discussion.

Jakob Dupont, MD MA

Our CEO Wyatt McDonnell moderated a panel at #BIO2024 last week in San Diego! It was a great audience turnout, for the panel session on “AI’s impact on oncology drug development.” 🧬🧬🧬 Thanks to the panelists Jakob Dupont, MD MA , Sofinnova Investments , Kamni Vijay, PhD , Enable Medicine , Daniel-Adriano S. , Monod Bio and Andrei Georgescu, Ph.D. from Vivodyne for joining this discussion. Looking forward to the next event! Great to see everyone.

We’re excited to welcome Dr. Neela Patel to our Board of Directors. Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals. “We are thrilled to welcome Neela as an independent Board member,” said Dr. Wyatt McDonnell , CEO & Co-Founder, Infinimmune. “With over 25 years of leadership experience spanning drug discovery, development, strategic partnerships, and corporate development, she brings invaluable expertise to Infinimmune. Her proven track record of pipeline development and strategic collaborations will be invaluable as we continue to advance our programs and pursue new opportunities for growth.” Read the release: 👇👇 https://lnkd.in/eWcAxajx

Join us next month at #BIO2024 in San Diego! Our CEO & Co-Founder Wyatt McDonnell will moderate a panel on “AI’s Impact on Oncology Cancer Drug Development.” 🧬🧬🧬 Featuring panelists: Jakob Dupont, MD MA , Executive Partner, Sofinnova Investments Kamni Vijay, PhD , CEO, Enable Medicine Andrei Georgescu, Ph.D. , CEO, Vivodyne Daniel-Adriano S. , CEO, Monod Bio Abraham Heifets , CEO, Atomwise More info about the panel: https://lnkd.in/exaCggm8

INFI

COM:INFINIMMUNE

Infinimmune